The average salary of the 28 provinces has been released. Have the medical workers met the standard?

[Pharmaceutical Network Market Analysis] Recently, the topic of "The Average Salary of 28 Provinces in 2021" has aroused widespread concern and heated discussion among netize.
According to incomplete statistics, except for Shanghai, Hubei, and Tibet, 28 provinces have disclosed the average annual salary of employees in urban units in 202 Overall, the average salary of employees in urban non-private units (106,837 yuan) is higher than that in urban private uni.
The average annual salary of employees in private units in many industries is also relatively hi.
Taking Guangdong Province as an example, in terms of industry categories, the top average annual wages are the information transmission, software and information technology service industries with 140,251 yuan, the financial industry with 133,540 yuan, and the scientific research and technical service industries with 86,978 yu.
The three industries with the highest speed are mining, finance, and electricity, heat, gas and water production and supply, which increased by 36%, 29% and 18% respective.
So, what is the salary level of medical staff? Especially in the context of the growing demand for vaccines and testing in recent years, has the income of medical professionals increased? The average salary of the 28 provinces has been releas.
Have the medical workers met the standard? (Image source: Pharmaceutical Network) The 425 companies in the medical and health field counted on the Wind platform will have a per capita salary of 168,900 yuan in 202From the perspective of sub-sectors, the average annual salary includes medical devices, chemical drugs, biological products, and medical beauty, while the per capita salary in the pharmaceutical business and traditional Chinese medicine industries is relatively comm.
Judging from the companies with the highest average annual salary in 2021, the average annual salary of Rejing Bio, Dizhe Pharmaceutical, BeiGene, Shuoshi Bio, and Asieris are all above 500,000 yu.
Among them, the per capita annual salary of Rejing Bio is as high as 885,000 yu.
Although the salary of the company's executives has raised the average salary, from the perspective of business development, it can also be seen that its rapid business development has affected the salary of employees of the compa.
Rejing Bio's business mainly involves the detection industry, which has been booming in recent yea.
In 2021 alone, the company's in vitro diagnostic product sales revenue will increase by 937% compared to 202It is understood that in the first quarter of 2021, the company's two new antigen rapid detection reagent products have been certified by the German Federal Institute for Drugs and Medical Devices for free home testing, and can be sold in supermarkets, pharmacies, and Internet stores in Germa.
After the product was certified, the company's foreign trade orders also ushered in an explosive grow.
In 2021, the company's overseas revenue exceeded 5 billion yuan, accounting for 94% of the company's annual operating inco.
The 2021 annual equity distribution of Rejing Biology will be 50 yuan from 10 to The company also attaches great importance to the cultivation of R&D talen.
In 2021, the number of R&D personnel will increase by 80% to 237, and half of them will be young people under 3 In 2021, the average salary of the company's R&D personnel will be 230,800 yuan, and the income will increase by 435% year-on-ye.
Although Dizhe Pharmaceuticals is not profitable, as a globally competitive innovation-driven biopharmaceutical company, it is in a period of important R&D investme.
The company attaches great importance to R&.
As of June 2021, Dizhe Pharmaceuticals has There are 169 employees, of which 59 of the management team and R&D team have rich experience working in AstraZene.
After continuing to invest a lot of research and development expenses, the company's research and development products continue to make progre.
Among them, the faster product pipelines DZD9008 and DZD4205 are in the international multi-center phase II single-arm pivotal clinical trials, and other product development pipelines are in clinical phase I or preclinical sta.
In addition, according to the 2021 annual report, during the reporting period, the remuneration of the directors, supervisors and senior management of Dizhe Pharmaceuticals totaled 36465 million yu.
Chairman, general manager and chief scientist XIAOLIN ZHANG received a total pre-tax remuneration of 17277 million yuan from the company, and director, board secretary and financial director Lv Hongbin received a total pre-tax remuneration of 1889 million yuan from the compa.
Relatively speaking, the per capita salary of pharmaceutical business and traditional Chinese medicine companies is generally relatively l.
According to the analysis, the pharmaceutical business industry has been mainly affected by the rapid development of online pharmacies in recent yea.
Many brick-and-mortar pharmacies are struggling, and the shuffling of small and medium-sized enterprises is intensified, such as closing down and being acquired, which in turn affects the salaries of employe.
Although Chinese medicine companies have been supported by favorable policies in recent years, their business is relatively traditional and innovation is we.
In addition, some companies do not pay attention to R&D, which makes it difficult to drive high performance growth, and employees will inevitably become low-income pee.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.